Mirati Therapeutics
Mirati Therapeutics is a San Diego-based biopharmaceutical company that develops targeted small-molecule oncology therapies, most notably the FDA-approved KRAS G12C inhibitor Krazati (adagrasib) for non-small cell lung cancer and pancreatic cancer. Acquired by Bristol Myers Squibb for $4.8 billion in January 2024.
- Company typePrivate
- Founded1995
- HeadquartersSan Diego, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mirati Therapeutics does
Mirati Therapeutics is a San Diego, California-based biopharmaceutical company founded in 1995 that develops targeted small-molecule oncology therapies, with a domain specialization in KRAS-mutated cancers that were historically considered undruggable. Its lead asset is Adagrasib (marketed as Krazati), an FDA-approved KRAS G12C inhibitor indicated for KRAS G12C-mutated non-small cell lung cancer and pancreatic cancer; the broader pipeline included an early-phase SOS1 inhibitor program targeting the RAS pathway for combination use (later removed from the Bristol Myers Squibb pipeline in October 2025).
The company historically generated revenue via traditional biopharmaceutical commercialization of its approved oncology product through specialty pharmacy, hospital formulary, and oncology treatment center channels, following FDA approval. It served oncologists, healthcare providers, and KRAS G12C-mutated cancer patients, particularly those with pancreatic cancer and non-small cell lung cancer, addressing high unmet medical need. Capital was raised primarily through public equity offerings post-IPO on NASDAQ under ticker MRTX, including a $500 million offering in November 2021 and an upsized $345 million offering in August 2023.
In January 2024, Bristol Myers Squibb acquired Mirati Therapeutics for $4.8 billion as a strategic move to bolster its oncology portfolio and offset upcoming patent cliffs on blockbuster drugs such as Revlimid and Eliquis. Mirati now operates as a wholly-owned subsidiary of BMS, with its assets (including Krazati) integrated into BMS's broader oncology franchise. Prior to the acquisition, leadership included CEO and President Charles M. Baum, Chief Scientific Officer James Christensen, COO Daniel Faga, and director-level logistics head Kevin Hickman.
Mirati Therapeutics firmographics
Firmographics- Name
- Mirati Therapeutics
- Legal name
- Mirati Therapeutics, Inc.
- Website
- https://mirati.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Mirati Therapeutics is a San Diego-based biopharmaceutical company that develops targeted small-molecule oncology therapies, most notably the FDA-approved KRAS G12C inhibitor Krazati (adagrasib) for non-small cell lung cancer and pancreatic cancer. Acquired by Bristol Myers Squibb for $4.8 billion in January 2024.
- Ownership category
- akta.pro rank
Mirati Therapeutics industry classification
Industry- Product category
- Targeted Oncology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industry
- Gastrointestinal Oncology (HLAKAFAK)
Keywords
Where Mirati Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mirati Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Mirati Therapeutics product offering
Product offeringCore offering
Mirati Therapeutics develops and commercializes targeted oncology therapies, with its lead product Krazati (adagrasib), an FDA-approved KRAS G12C inhibitor for the treatment of KRAS G12C-mutated non-small cell lung cancer and pancreatic cancer. The company also pursued a pipeline of small molecule targeted therapies, including a SOS1 inhibitor program targeting RAS pathway signaling, designed to address historically undruggable oncogenic mutations. Products were distributed through specialty pharmacies, hospital formularies, and oncology treatment centers following FDA approval.
Differentiator
Problem solved
Functional benefit
Products and services
- Krazati (adagrasib) Adagrasib, marketed as Krazati, is a KRAS G12C inhibitor indicated for the treatment of KRAS G12C-mutated cancers, including non-small cell lung cancer and pancreatic cancer, providing a targeted therapeutic option for patients with these specific oncogenic mutations.
Companies that use Mirati Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Mirati Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Mirati Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bristol Myers SquibbcoreBristol Myers Squibb acquired Mirati Therapeutics for $4.8 billion in January 2024 to strengthen its oncology portfolio, acquiring Krazati (adagrasib) and the broader pipeline including a SOS1 inhibitor program. The acquisition was part of BMS's strategy to address patent cliff challenges and expand its growth portfolio in oncology, particularly pancreatic cancer treatment.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Mirati Therapeutics competitors and assessment
Company assessmentDirect peers
- Erasca: Erasca is a precision oncology company focused on the MAPK pathway with multiple KRAS and downstream inhibitor programs, overlapping directly with Mirati's RAS-pathway targeting approach.
- Amgen: Amgen developed sotorasib (Lumakras), the first FDA-approved KRAS G12C inhibitor, directly competing with Mirati's Krazati in KRAS G12C-mutated NSCLC and across combination-therapy development.
- Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing a broad portfolio of RAS-targeted inhibitors including KRAS G12C, G12D, and pan-RAS assets, directly overlapping Mirati's RAS-pathway strategy.
Broad incumbents
- Pfizer: Pfizer is a global oncology incumbent with a broad targeted-therapy and combination pipeline that overlaps Mirati's KRAS franchise, particularly through PD-1/PD-L1 combination opportunities.
- AstraZeneca: AstraZeneca is a global oncology incumbent developing KRAS G12D inhibitors and a broad targeted-oncology pipeline, competing with Mirati's assets as part of a much larger commercial portfolio.
- Merck & Co. Merck is a global oncology leader combining Keytruda (PD-1) leadership with a targeted-therapy pipeline that intersects Mirati's KRAS franchise, particularly in combination therapy settings.
- Genentech (Roche): Genentech/Roche is a major oncology incumbent with a broad targeted-therapy pipeline including KRAS and MAPK-pathway assets, providing indirect competition across indications Mirati serves.
- Bristol Myers Squibb: BMS acquired Mirati in January 2024 for $4.8B and now owns Krazati; it is the parent oncology incumbent with deep I-O combinations (Opdivo, Yervoy) that shape Mirati's commercial and clinical trajectory.
Emerging players
- BeiGene: BeiGene is a global oncology biotech with a growing targeted-therapy pipeline and strong commercialization capabilities, making it an emerging peer in precision oncology where Mirati competed.
- Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology biotech developing small molecule therapies against allosteric oncogenic mutations, sharing Mirati's targeted-kinase approach but with a broader mutation-agnostic platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Mirati Therapeutics social profiles
Digital presenceMirati Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirati Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Mirati Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirati Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirati Therapeutics
What does Mirati Therapeutics do?
Mirati Therapeutics develops and commercializes targeted oncology therapies, with its lead product Krazati (adagrasib), an FDA-approved KRAS G12C inhibitor for the treatment of KRAS G12C-mutated non-small cell lung cancer and pancreatic cancer. The company also pursued a pipeline of small molecule targeted therapies, including a SOS1 inhibitor program targeting RAS pathway signaling, designed to address historically undruggable oncogenic mutations. Products were distributed through specialty pharmacies, hospital formularies, and oncology treatment centers following FDA approval.
Is Mirati Therapeutics a public or private company?
Mirati Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Mirati Therapeutics founded?
Mirati Therapeutics was founded in 1995. It employs 501 to 1,000 people.
Where is Mirati Therapeutics based?
Mirati Therapeutics is headquartered in San Diego, United States, in the North America region.
Who are Mirati Therapeutics's main competitors?
Direct peers on record are Erasca, Amgen and Revolution Medicines. Broad incumbents are Pfizer, AstraZeneca, Merck & Co., Genentech (Roche) and Bristol Myers Squibb. Emerging players are BeiGene and Black Diamond Therapeutics.
Does Mirati Therapeutics have an API?
No public API is recorded for Mirati Therapeutics.
What industry is Mirati Therapeutics in?
Mirati Therapeutics's product category is Targeted Oncology Therapeutics. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAKAFAK, Gastrointestinal Oncology. Its NAICS code is 3254 and its SIC code is 2834.